AnalystsManeka MirchandaneyManeka Mirchandaney's Stock Forecasts
AnalystsManeka Mirchandaney
Sectors:
Industries:
Analyst Ranking
Bottom 14%
#4824 out of 5550 analysts
Average Return
-5.98%
Win Rate
46%6 out of 13
Risk vs Reward
Poor
Good
Maneka Mirchandaney's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Crinetics Pharmaceuticals IncCRNX | +131.03% | $36.77 | $84.95 | 2026-05-15 - 2026-09-01 | Buy |
Crinetics Pharmaceuticals IncCRNX | +93.25% | $26.08 | $50.40 | 2023-09-11 - 2024-09-10 | Buy |
Viridian Therapeutics IncVRDN | +46.67% | $16.82 | $24.67 | 2026-05-15 - 2026-10-30 | Buy |
Seagen IncSGEN | +42.15% | $160.91 | $228.74 | 2023-02-16 - 2023-12-13 | Buy |
Viridian Therapeutics IncVRDN | +30.94% | $18.84 | $24.67 | 2026-04-02 - 2026-10-30 | Buy |
Maneka Mirchandaney Analyst Color
Get additional color on Maneka Mirchandaney's coverage of popular stocks
Maneka Mirchandaney's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Incyte CorpINCY | 3 | Hold | $127.00 | +5.49% | Maintains | 2 days ago |
Viridian Therapeutics IncVRDN | 3 | Buy | $26.00 | +5.39% | Maintains | 6 months ago |
Crinetics Pharmaceuticals IncCRNX | 3 | Buy | $88.00 | +3.59% | Maintains | 6 months ago |
Mink Therapeutics IncINKT | 2 | Buy | $3.00 | N/A | Maintains | 4 years ago |
Seagen IncSGEN | 2 | Buy | $175.00 | N/A | Upgrades | 4 years ago |
Neuphoria Therapeutics IncNEUP | 1 | Buy | $17.00 | N/A | Initiates Coverage On | 5 years ago |
Werewolf Therapeutics IncHOWL | 1 | Buy | $23.00 | N/A | Initiates Coverage On | 5 years ago |
Finch Therapeutics Group IncFNCH | 1 | Buy | $1,020.00 | N/A | Initiates Coverage On | 6 years ago |
Global Blood Therapeutics IncGBT | 1 | Buy | $102.00 | N/A | Initiates Coverage On | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.